FARE - Food Allergy Research & Education Logo
Take Action
Help Us Accelerate Food Allergy Research

Join over 10,000 individuals and families managing food allergies who are sharing their food allergy stories and making a critical difference, helping to speed the search for new treatments and informing life-changing improvements in patient care.

Donate
Donate Today

You can help improve 32 million lives by supporting Food Allergy Research & Education (FARE) with your tax-deductible gift today.

FARE - Food Allergy Research & Education Logo

Clinical Trial Finder

LYell SYndrome MEsenchymal Stromal Cells Treatment

Study Purpose

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs. To date, no curative drug has demonstrated with a good level of evidence its ability to promote SJS and TEN healing and could contribute to earlier reepithelialisation. Mesenchymal stroma cells (MSCs) therapy represents a new therapeutic approach. eg, in patients with cardiovascular diseases, neurological diseases, renal transplantation, lung diseases as acute respiratory distress syndrome. Recently, MSCs have been proposed in both burn wound healing with a significantly decrease of the unhealed burn area and in cutaneous radiation. Moreover, MSCs have immunomodulation properties potentially effective in refractory acute and chronic graft versus host disease (GVHD) by improving thymic function and induction of Tregs. Indeed, MSCs are able to migrate to inflamed tissues after stimulation by pro-inflammatory cytokines and to modulate the local inflammatory reactions. MSCs have also demonstrated their ability to promote tissue remodelling, angiogenesis and immunomodulation through either differentiation or secretion of several growth factors such as VEGF, basic FGF and various cytokines. Therefore, combining their immunomodulation effect and secretion of soluble factors involved in wound repair, MSCs might be valuable as a cell therapy strategy for promoting cutaneous healing in SJS-TEN syndrome and subsequently decrease the morbi-mortality.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients ≥ 18 and ≤ 75 years-old.
  • - Admission ≤ 10 days after the index date (date of the first symptoms of the disease) - Patient with confirmed SJS-TEN diagnosis hospitalized in the department of Dermatology or intensive care medicine.
  • - At least 10 % of detachable-detached body surface area at any time during the first 10 days after the index date (date of the first symptoms of the disease) - Who, after the nature of the study has been explained to them or a support person (if applicable), and prior to any protocol specific procedures being performed, have given written consent according to local regulatory requirements.
  • - Affiliated to a social security scheme.

Exclusion Criteria:

  • - Pregnant or breastfeeding women.
  • - History of malignant disease within the past ten years and or presence of metastasis.
  • - Positive serology for HIV.
  • - Active infection for hepatitis B or C.
  • - Detection of Coronavirus SARS CoV-2 RNA on admission (positive RT-PCR), if performed in the usual care.
  • - Decompensated cardiac failure.
  • - Uncontrolled epilepsia.
  • - Previous history of allogenic bone marrow transplantation.
  • - Participation in other interventional drug research Patient deprived of liberty by a judicial or administrative decision or under the protection of justice.
  • - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the research protocol and follow-up schedule.
  • - Patient under tutorship or curatorship.
  • - Patient under psychiatric care according to art.
L1121-6 CSP

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT04711200
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

 Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 Assistance Publique - Hôpitaux de Paris
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 Saskia Oro, PhD
Principal Investigator Affiliation [email protected]
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 Other
Overall Status Recruiting
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Epidermal Necrolysis, Lyell Syndrome, Toxic Epidermal Necrolysis, Overlap Syndrome, Mesenchymal Stromal Cells, Adipose Derived Stromal Cells
Arms & Interventions

Arms

Experimental: Adipose derived stromal cells intravenously injected

Interventions

Drug: - Adipose derived stromal cells intravenously injected

2×10^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Henri Mondor, Créteil 3022530, France

Status

Recruiting

Address

Henri Mondor

Créteil 3022530, ,

Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Education Research Peanut Tree Nut Soy Sesame Milk Egg Wheat Adults with Allergies Children with Food Allergies Newly Diagnosed Adolescents and Teens